MALCOLM BRENNER to Genetic Therapy
This is a "connection" page, showing publications MALCOLM BRENNER has written about Genetic Therapy.
Connection Strength
7.424
-
Improving the safety of T-Cell therapies using an inducible caspase-9 gene. Exp Hematol. 2016 Nov; 44(11):1013-1019.
Score: 0.389
-
Mesenchymal Stromal Cells for Linked Delivery of Oncolytic and Apoptotic Adenoviruses to Non-small-cell Lung Cancers. Mol Ther. 2015 Sep; 23(9):1497-506.
Score: 0.361
-
An Inducible Caspase-9 Suicide Gene to Improve the Safety of Therapy Using Human Induced Pluripotent Stem Cells. Mol Ther. 2015 Sep; 23(9):1475-85.
Score: 0.359
-
Is cancer gene therapy an empty suit? Lancet Oncol. 2013 Oct; 14(11):e447-e456.
Score: 0.320
-
Introducing molecular therapy--methods & clinical development. Mol Ther. 2013 Jun; 21(6):1105.
Score: 0.313
-
Introducing a new ASGCT forum for publication of methodology and clinical development in gene, cell, and oligonucleotide therapies. Mol Ther. 2012 Nov; 20(11):2005-6.
Score: 0.301
-
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011 Dec 01; 118(23):6050-6.
Score: 0.279
-
The eyes have it. Mol Ther. 2010 Mar; 18(3):451-2.
Score: 0.250
-
Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?". Hum Gene Ther. 2009 Nov; 20(11):1229-39.
Score: 0.244
-
Overview of gene therapy clinical progress including cancer treatment with gene-modified T cells. Hematology Am Soc Hematol Educ Program. 2009; 675-81.
Score: 0.230
-
The continuing contribution of gene marking to cell and gene therapy. Mol Ther. 2007 Apr; 15(4):666-76.
Score: 0.202
-
Targeted delivery of adenoviral vectors by cytotoxic T cells. Blood. 2004 Oct 15; 104(8):2272-80.
Score: 0.167
-
Chimeric T-cell receptors for the targeting of cancer cells. Acta Haematol. 2003; 110(2-3):154-9.
Score: 0.152
-
Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas. J Immunother Cancer. 2021 05; 9(5).
Score: 0.135
-
Gene transfer and the treatment of haematological malignancy. J Intern Med. 2001 Apr; 249(4):345-58.
Score: 0.135
-
Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector. Hum Gene Ther. 2000 Jul 01; 11(10):1477-88.
Score: 0.128
-
Reports of adenovector "death" are greatly exaggerated. Mol Ther. 2000 Mar; 1(3):205.
Score: 0.125
-
Gene transfer by adenovectors. Blood. 1999 Dec 15; 94(12):3965-7.
Score: 0.123
-
"Resistance is futile". Gene Ther. 1999 Oct; 6(10):1646-7.
Score: 0.121
-
"The end of the beginning": molecular and cellular biology of gene therapy keystone. 14-20 January 1999. Biochim Biophys Acta. 1999 Jul 29; 1424(1):R5-9.
Score: 0.120
-
Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice. Nat Med. 1998 Nov; 4(11):1253-60.
Score: 0.114
-
Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum Gene Ther. 1998 Jun 10; 9(9):1303-11.
Score: 0.111
-
Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol. 2018 04 10; 36(11):1128-1139.
Score: 0.108
-
Applications of gene transfer in hematologic malignancy. Recent Results Cancer Res. 1998; 144:60-9.
Score: 0.107
-
Gene and cell transfer for specific immunotherapy. Vox Sang. 1998; 74 Suppl 2:87-90.
Score: 0.107
-
Seek and You Will Not Find: Ending the Hunt for Replication-Competent Retroviruses during Human Gene Therapy. Mol Ther. 2018 01 03; 26(1):1-2.
Score: 0.107
-
Hematological malignancies. FASEB J. 1997 Jul; 11(8):640-8.
Score: 0.104
-
Emerging applications of gene transfer in the hematopoietic cancers. J Pediatr Hematol Oncol. 1997 Jan-Feb; 19(1):1-6.
Score: 0.100
-
Gene transfer in haematological malignancy. Ann Med. 1996 Dec; 28(6):491-7.
Score: 0.100
-
Gene marking and gene therapy for transplantation medicine. J Hematother. 1996 Oct; 5(5):553-5.
Score: 0.099
-
Gene marking. Gene Ther. 1996 Apr; 3(4):278-9.
Score: 0.095
-
The contribution of marker gene studies to hemopoietic stem cell therapies. Stem Cells. 1995 Sep; 13(5):453-61.
Score: 0.091
-
A Safeguard System for Induced Pluripotent Stem Cell-Derived Rejuvenated T Cell Therapy. Stem Cell Reports. 2015 Oct 13; 5(4):597-608.
Score: 0.091
-
Human somatic gene therapy: progress and problems. J Intern Med. 1995 Mar; 237(3):229-39.
Score: 0.088
-
The use of cytokines to improve gene transfer to human hematopoietic stem cells. Cytokines Mol Ther. 1995 Mar; 1(1):3-9.
Score: 0.088
-
Gene transfer into human hemopoietic progenitor cells. Br Med Bull. 1995 Jan; 51(1):167-91.
Score: 0.087
-
Genetic marking and manipulation of hematopoietic progenitor cells using retroviral vectors. Immunomethods. 1994 Dec; 5(3):204-10.
Score: 0.087
-
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014 Mar 10; 32(8):798-808.
Score: 0.081
-
Clinical success of complex biological therapies: be careful what you wish for... Mol Ther. 2010 Oct; 18(10):1737-8.
Score: 0.065
-
Progress and prospects: gene therapy clinical trials (part 2). Gene Ther. 2007 Nov; 14(22):1555-63.
Score: 0.053
-
An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005 Jun 01; 105(11):4247-54.
Score: 0.044
-
LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study. Lancet Oncol. 2024 Apr; 25(4):488-500.
Score: 0.041
-
Liposomal enhancement of the antitumor activity of conditionally replication-competent adenoviral plasmids. Mol Ther. 2004 Apr; 9(4):489-95.
Score: 0.041
-
American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol Ther. 2003 Aug; 8(2):180-7.
Score: 0.040
-
Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. Mol Ther. 2003 Jun; 7(6):748-54.
Score: 0.039
-
[Gene therapy of childhood cancers: current status and perspectives]. Bull Cancer. 2003 Mar; 90(3):227-38.
Score: 0.038
-
Is retroviral gene marking too dangerous to use? Cytotherapy. 2003; 5(3):190-3.
Score: 0.038
-
Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials. Mol Ther. 2023 03 01; 31(3):801-809.
Score: 0.038
-
Cancer vaccines: dream, reality, or nightmare? Clin Exp Med. 2002 Nov; 2(3):109-18.
Score: 0.038
-
Evidence-based regulation--a personal view. Mol Ther. 2002 Aug; 6(2):137.
Score: 0.037
-
Response to "systemic adenovirus delivery". Mol Ther. 2002 Aug; 6(2):138.
Score: 0.037
-
Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses. Mol Ther. 2002 Mar; 5(3):233-41.
Score: 0.036
-
Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus--positive Hodgkin's lymphoma. Int J Cancer. 2001 Sep 01; 93(5):706-13.
Score: 0.035
-
Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene Ther. 2001 Jun; 8(12):930-7.
Score: 0.034
-
Selection of human antitumor single-chain Fv antibodies from the B-cell repertoire of patients immunized against autologous neuroblastoma. Med Pediatr Oncol. 2000 Dec; 35(6):692-5.
Score: 0.033
-
Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease. Hum Gene Ther. 2000 Jul 01; 11(10):1465-75.
Score: 0.032
-
Human gene marker/therapy clinical protocols. Hum Gene Ther. 2000 Apr 10; 11(6):919-79.
Score: 0.031
-
Human gene marker/therapy clinical protocols. Hum Gene Ther. 1999 Dec 10; 10(18):3067-123.
Score: 0.031
-
Cure of leukemia. Semin Hematol. 1999 Oct; 36(4 Suppl 7):73-83.
Score: 0.030
-
Retinoblastoma treatment. Science. 1999 Jul 30; 285(5428):663-4.
Score: 0.030
-
Gene therapy in a rodent model of Parkinson's disease using differentiated C6 cells expressing a GFAP-tyrosine hydroxylase transgene. Life Sci. 1999; 65(5):483-91.
Score: 0.029
-
Astrocyte-specific expression of tyrosine hydroxylase after intracerebral gene transfer induces behavioral recovery in experimental parkinsonism. Gene Ther. 1998 Dec; 5(12):1650-5.
Score: 0.029
-
Selective killing of glioma cell lines using an astrocyte-specific expression of the herpes simplex virus-thymidine kinase gene. Cancer Res. 1998 Oct 15; 58(20):4577-80.
Score: 0.028
-
Human gene marker/therapy clinical protocols. Hum Gene Ther. 1997 Dec 10; 8(18):2301-38.
Score: 0.027
-
Human gene marker/therapy clinical protocols. Hum Gene Ther. 1996 Dec 01; 7(18):2287-313.
Score: 0.025
-
Human gene marker/therapy clinical protocols. Hum Gene Ther. 1996 Aug 20; 7(13):1621-47.
Score: 0.024
-
Gene transfer to hematopoietic cells. N Engl J Med. 1996 Aug 01; 335(5):337-9.
Score: 0.024
-
Gene transfer and therapeutic drug monitoring. Ther Drug Monit. 1996 Aug; 18(4):322-7.
Score: 0.024
-
Gene therapy: socioeconomic and ethical issues. A roundtable discussion. Hum Gene Ther. 1996 Jun 10; 7(9):1139-44.
Score: 0.024
-
Vectors in cancer therapy: how will they deliver? Cancer Gene Ther. 1995 Dec; 2(4):291-7.
Score: 0.023
-
Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA317-G1Tk1SvNa.7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors. Hum Gene Ther. 1995 Sep; 6(9):1231-55.
Score: 0.023
-
European School of Oncology position paper. Gene therapy for the medical oncologist. Eur J Cancer. 1995; 31A(9):1531-7.
Score: 0.022
-
Gene transfer into human hematopoietic progenitor cells: a review of current clinical protocols. J Hematother. 1993; 2(1):7-17.
Score: 0.019
-
A phase 1/2 study of autologous neuroblastoma tumor cells genetically modified to secrete IL-2 in patients with high-risk neuroblastoma. J Immunother. 2008 Nov-Dec; 31(9):812-9.
Score: 0.014
-
Selection of chronic lymphocytic leukemia binding peptides. Cancer Res. 2003 Sep 01; 63(17):5213-7.
Score: 0.010
-
Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood. 2002 May 01; 99(9):3179-87.
Score: 0.009
-
Controversies and new approaches to treatment of Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 1998 Apr; 12(2):339-57.
Score: 0.007